3D SUSPENSION METHOD FOR GENERATING AUTOLOGOUS MELANOCYTE BY INDUCING IPS CELLS AND APPLICATION THEREOF
20200199531 ยท 2020-06-25
Inventors
Cpc classification
C12N2501/125
CHEMISTRY; METALLURGY
C12N2506/45
CHEMISTRY; METALLURGY
A61K35/36
HUMAN NECESSITIES
C12N5/0062
CHEMISTRY; METALLURGY
C12N2501/115
CHEMISTRY; METALLURGY
A61K35/545
HUMAN NECESSITIES
International classification
Abstract
The present invention relates to the field of biological technology and relates to a method for growing cells, specifically relating to a 3D suspension method for growing autologous melanocyte by inducing iPS cells, and to an application thereof. Said method of the present invention detaches the iPS cells into single cells and uses 3D culture plates to grow embryoid bodies, which all have uniform shapes and sizes. The early term induction process 14 days before the differentiation replaces 2D planar monolayer cultivation with 3D suspension cultivation, thereby lowering the rate of epithelioid cell occurrences during the differentiation process, enhancing the differentiation efficiency of melanocytes, optimizing the pre-differentiation embryoid body selection, single cell detachment time, and culture medium components, and improving the proliferation state of melanocyte. The melanocyte obtained by means of the present invention has the characteristics of being highly similar to normal melanocyte in vitro and exhibits features markedly superior to normal melanocyte during in vivo transplantation.
Claims
1. A method of inducing iPS cells to generate autologous melanocytes by using 3D suspension system, characterized in that, said method comprises the following steps: a) embryoid body formation by using single cell method iPS single cell dissociation enzyme is added into iPS clones for dissociation; mTeSR medium is added and cells are pipetted gently to form iPS single cell suspension; after centrifugation, the supernatant is discarded, then mTeSR medium is added to cell pellet for resuspension; iPS single cells are counted and inoculated into three dimensional culture plate; ROCK inhibitor is added; after culture, embryo bodies having uniform morphology and size are obtained; the embryo bodies are aspirated by gentle pipette and transferred to a low-attachment plate for continued culture, and the medium is changed every day; and b) 3D suspension differentiation: (1) 3D early-stage differentiation: the embryoid bodies obtained in step a) are transferred into differentiation medium for early-stage differentiation, (2) mid-stage attached differentiation: after the early-stage differentiation in the above step b)(1), the embryoid bodies are transferred to a fibronectin-coated culture plate for mid-stage attached culture, the differentiation medium components remain unchanged, and the embryoid bodies attach to the plate and grow, and (3) late-stage differentiation: after attached culture in the above step b)(2), the embryoid bodies are dissociated into single cells, inoculated into a fibronectin-coated culture plate, and subjected to late maturation induction in differentiation medium, when the cell density reaches 90%, passage is performed with dissociation enzymes, and mature melanocytes are obtained after 35 to 42 days of differentiation.
2. The method for generating autologous melanocytes according to claim 1, characterized in that, the three dimensional culture plate for iPS single cells inoculation is Elplasia three dimensional plate (24 wells) and the inoculation density is 510.sup.5 cells per well.
3. The method for generating autologous melanocytes according to claim 1, characterized in that, the continued culture lasts for 5-10 days until embryoid bodies reach 300-500 m in diameter.
4. The method for generating autologous melanocytes according to claim 1, characterized in that, the embryoid bodies in step b) (1) are suspended in the low-attachment plates during the early-stage differentiation.
5. The method for generating autologous melanocyte according to claim 1, characterized in that, the early-stage differentiation in step b) (1) lasts for 14 days and mid-stage attached differentiation in step b) (2) lasts for 7 days.
6. The method for generating autologous melanocyte according to claim 1, characterized in that, the embryoid bodies after attached culture in step b) (3) are embryoid bodies on day 21 of differentiation.
7. The method for generating autologous melanocyte according to claim 1, characterized in that, the density of inoculation in step b) (3) is 210.sup.4/cm.sup.2.
8. The method for generating autologous melanocyte according to claim 1, characterized in that, the differentiation medium described in step b) (3) includes: 50% (v/v) L-Wnt3a cell conditioned medium, 30% low-glucose DMEM, 20% MCDB 201 medium, 0.05 M dexamethasone, lx insulin-transferrin-selenium, 1 mg/ml linoleic acid-bovine serum albumin, 10.sup.4 M L-ascorbic acid, 50 ng/ml stem cell factor, 100 nM EDN3, 20 pM cholera toxin, 4 ng/ml bFGF and 0.5% fetal bovine serum.
9. The use of a melanocyte prepared according to the method of claim 1, characterized in that, the melanocyte is used for cellular transplantation or drug screening for treatment of depigmented diseases.
10. The use according to claim 9, characterized in that, the depigmented diseases is vitiligo.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
EMBODIMENTS
[0034] The present invention is further described below with reference to the examples, but it should not be understood that the subject scope of the present invention is limited only to the following examples. Various substitutions and modifications can be made according to ordinary technical knowledge and conventional means in the art without departing from the technical ideas of the present invention, all of which should be included within the protection scope of the present invention. The experimental methods used in the examples which have no special instructions are all conventional methods. The materials, reagents and the like used in the following examples without special instructions can be obtained from a commercial route.
[0035] In the present invention, iPS cells, iPSCs-2 cells and iPSCs-3 cells are generated from human skin fibroblasts by virus transfection method and the characteristics of generated iPS cells are identified as shown in
Example 1
[0036] Conventional Method (2D Differentiation):
[0037] As shown in
Example 2
[0038] a. Embryoid Body Formation by Using Single Cell Method
[0039] When iPS cell clones grow to a suitable size, add iPS single cell dissociation enzyme ACCUTASE (Innovative Cell Technologies). Place for 5-7 min at room temperature. Add mTeSR (Stemcell Technologies) medium and gently pipette to form iPS single cell suspension. Centrifuge and discard the supernatant. Add mTeSR medium to resuspend and count. Inoculate iPS single cells into Elplasia 3D culture plate (Kuraray) (
[0040] b. 3D Suspension Differentiation Process
[0041] (1) 3D Early-Stage Differentiation:
[0042] When embryoid bodies reach 300-500 m in diameter after being cultured for 5-10 days in low attachment plate (
[0043] The differentiation medium includes: 50% (v/v) L Wnt-3a cell conditioned medium, 30% low-glucose DMEM (Gibco), 20% MCDB 201 (Sigma-Aldrich), 0.05 M dexamethasone (Sigma-Aldrich), lx insulin-transferrin-selenium (Sigma-Aldrich), 1 mg/ml linoleic acid-bovine serum albumin (Sigma-Aldrich), 10.sup.4 M L-ascorbic acid (Sigma-Aldrich), 50 ng/ml stem cell factor (Sigma-Aldrich), 100 nM EDN3 (American Peptide Company), 20 pM cholera toxin (Sigma-Aldrich), 50 nM 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Sigma-Aldrich) and 4 ng/mL bFGF (Wako).
[0044] (2) Mid-Stage Attached Differentiation
[0045] Preparation of fibronectin (BD Biosciences)-coated culture plate: for each well of a 6-well plate, add 1 ml DPBS and 20 l fibronectin stock-solution (1 mg/ml). Pipette gently for homogeneous mixing. Incubate at room temperature for 1 h. Discard and wash once with 1 ml DPBS for the next step.
[0046] Transfer embryoid bodies which have been differentiated for 14 days in step (1) to above mentioned fibronectin-coated culture plates for mid-stage attached differentiation with the components of differentiation medium remaining unchanged. Attached embryoid bodies grow for another 7 days. At this time, a great number of dendritic cells are generated in the peripheral area of embryoid bodies and epithelium-like cells are rarely found (
[0047] (3) Late-Stage Differentiation
[0048] Dissociate the embryoid bodies after attached differentiation in Step (2) into single cells using TrypLE Select (Invitrogen) and inoculate them onto fibronectin-coated culture plate (on day 21 of differentiation). The inoculation density is 210.sup.4/cm.sup.2. Late-stage differentiation is performed in the optimized differentiation medium. When the cell density reached 90%, the cells are dissociated using TrypLE Select and passaged. The dendrites become more and more typical and these cells proliferate quickly (
[0049] The optimized differentiation medium includes: 50% (v/v) L-Wnt3a cell conditioned medium, 30% low-glucose DMEM medium, 20% MCDB 201 medium, 0.05 M dexamethasone, lx insulin-transferrin-selenium, 1 mg/ml linoleic acid-bovine serum albumin, 10.sup.4 M L-ascorbic acid, 50 ng/ml stem cell factor, 100 nM EDN3, 20 pM cholera toxin, 4 ng/ml bFGF and 0.5% FBS.
Example 3
[0050] 3D Suspension Differentiation by Using Embryoid Bodies with Different Culture Days and Sizes:
[0051] The effect of different culture days and sizes of embryoid bodies on melanocyte differentiation is studied in the present invention. As shown in
Example 4
[0052] Effect of Different Time Points of Single Cell Dissociation on Melanocyte Differentiation:
[0053] In the process of single cell dissociation of the embryoid bodies after attached culture in Example 2, the present invention compared the effects of different time points of single cell dissociation on the proliferation state of induced melanocytes. Single cell dissociation and passage of embryoid bodies are conducted on day 14, 21 and 28 of differentiation. As shown in
Example 5
[0054] Effect of the Serum with Different Concentrations on Melanocyte Proliferation:
[0055] In the culture process after single cell dissociation according to Example 2, the effects of adding serum FBS (Gibco) and knockout serum replacement (KSR, Gibco) with different concentrations in the differentiation medium on melanocyte growth are compared in the present invention. As shown in
Example 6
[0056] Identification of In Vitro Characteristics of Autologous Melanocytes Generated by Inducing iPS Cells Using 3D Suspension System:
[0057] The in vitro characteristic comparison is performed between the induced melanocytes prepared by the method according to the present invention and the normal melanocyte, as shown in
Example 7
[0058] Identification of the In Vivo Function of the Induced Melanocytes Generated by 3D Suspension System:
[0059] The in vivo function comparison is performed between the induced melanocytes prepared according to the preparation method of the present invention and normal melanocytes. As shown in
[0060] Therefore, induced melanocytes obtained in this invention are obviously superior to normal melanocytes in terms of in vivo function, and they are more beneficial to future transplantation application.
Example 8
[0061] Application of 3D Suspension System on Different iPS Cell Lines:
[0062] The 3D suspension system for in vitro inducing iPS cells to generate autologous melanocytes was applied to the other two iPS cell lines: iPSCs-2 cells and iPSCs-3 cells, and a large number of mature melanocytes were efficiently induced, suggesting that the method has wide applicability. As shown in